Drug intelligence / Profile preview

Huangding Feixinping granules

Development stage: Unknown
Lead developer: Chongqing Hilan Pharmaceutical
Administration: Oral

Overview

Huangding Feixinping granules is a Traditional Chinese Medicine (TCM) therapeutic candidate developed by Chongqing Hillan Pharmaceutical for the management of chronic cor pulmonale (chronic pulmonary heart disease) during the remission phase. The formulation is specifically designed for patients exhibiting the 'heart-lung qi deficiency' syndrome, a TCM diagnostic pattern characterized by shortness of breath, fatigue, and palpitations. It is currently being evaluated in a Phase II clinical trial in China to assess its efficacy in improving exercise tolerance (measured by the 6-minute walk test), oxygen saturation, and overall quality of life over a 12-week treatment period.

Other names: 黄定肺心平颗粒

Beyond the preview

Go deeper on Huangding Feixinping granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huangding Feixinping granules.

Explore the full profile